GRIPPOL®
QUADRIVALENT
RUSSIA'S FIRST QUADRIVALENT
INACTIVATED SUBUNIT INFLUENZA VACCINE
INACTIVATED SUBUNIT INFLUENZA VACCINE
H1N1
5 µg
+
H3N2
5 µg
+
VICTORIA
5 µg
+
YAMAGATA
5 µg
+
ADJUVANT
AZOXIMER BROMIDE
500 µg
Grippol Quadrivalent is used for vaccination children and adults aged 6 to 60 years and over.
The vaccine is especially indicated for people:
- with chronic heart, blood, and vascular diseases;
- nervous system and brain diseases;
- respiratory pathologies, including bronchial asthma, COPD, and smokers;
- those affected by kidney disease, diabetes mellitus, and metabolic disorders, including obesity;
- persons with autoimmune, allergic diseases (except chicken protein allergy);
- sickly people;
- those affected by HIV and other immunodeficiencies;
- people who have a high risk of getting the flu or infecting others because of their occupation.
4 STRAINS
Grippol® Quadrivalent
protects against 4 strains of influenza:
2 influenza A viruses (A/H1N1 and A/H3N2)
and influenza B virus 2 lines (V/Yamagata and V/Victoria)
3 TIMES
Polyoxidonium®
Adjuvant in Grippol® Quadrivalent
enables to decrease the number of antigens in the vaccine by a factor of 3
and ensures a pronounced and long-lasting immune response to vaccination
QUALITY STANDARD
Grippol® Quadrivalent
meets modern quality standards for influenza vaccines
- Preservatives and Antibiotic Free
- Available in individual syringe doses with an atraumatic needle
- Produced according to international GMP standards
> 300M DOSES
Grippol® Quadrivalent
is based on the production technology of the Grippol® family of vaccines,
with a broad evidence base and a long history of use of over 300 million doses,
including in children from 6 months of age, the elderly, pregnant women, and persons with chronic diseases
Since 2012, WHO has been recommending annually that influenza B viruses of both Yamagata and Victoria1 strains be included in seasonal influenza vaccines.
TRIVALENT influenza vaccines contain antigens from 3 strains of influenza virus
H1N1
+
H3N2
+
VICTORIA
or
YAMAGATA
To date, only trivalent influenza vaccines have been used in the Russian Federation. In 2019, the Ministry of Health, together with Rospotrebnadzor, developed and approved a Phased Transition Plan for the use of quadrivalent vaccines to prevent influenza as part of the National Preventive Vaccination Calendar between 2019 and 2021.
Grippol®Quadrivalent contains 4 of the most common antigenic strains, which means that once it is administered and an immune response is formed, a person has a broader spectrum of protection against different types of viruses. Accordingly, the risk of contracting influenza is reduced.
4-valent influenza vaccines have greater prophylactic and pharmacoeconomic efficacy than 3-valent vaccines
According to estimates by the Center for Disease Control and Prevention for 2014-2034 (CDC, USA), the clinical outcomes and costs of replacing 3-valent with 4-valent vaccines will allow:2
to decrease the incidence of influenza В
by 16 million
cases
to decrease hospitalizations by 137,6 thousand
cases
to decrease the number of lethal outcomes by 16,1 thousand
cases
In Russia, a switch from the 3-valent to the 4-valent vaccine could prevent up to 265,8 thousand
cases of influenza per season3
Quadrivalent vaccines are included in National Immunization Programs in various countries of the world4
| Country/ Regulatory body |
Year when the recommendation was made | Age/group of vaccinated persons |
|---|---|---|
| WHO | 2012 | Pregnant, children under 5 years old, health care professionals, elderly, persons with chronic diseases |
| Germany | 2013 | Pregnant; children under 5 years old; health care professionals, elderly; persons with chronic diseases; people planning long journeys |
| USA | 2013 | Children from 6 months and adults |
| Hong Kong | 2013 | Children over the age of 3 and adults |
| Canada | 2014 | 6 months and over |
| France | 2014 | Children over the age of 3 and adults |
| Belgium | 2015 | Over the age of 2 |
| Brazil | 2014 | Elderly over 60 years old |
| Australia | 2015 | 6 months and over |
| Great Britain | 2013 | Children 2-7 years old and children at risk 2-18 years old |
GRIPPOL® QUADRIVALENT IS RUSSIA'S FIRST QUADRIVALENT INACTIVATED SUBUNIT INFLUENZA VACCINE
- Contains antigens of 2 influenza A subtypes (H1N1 and H3N2), 2 influenza B strains (Victoria and Yamaga), and the Polyoxidonium® immunoadjuvant
- Preservatives-free
- Available in individual syringe doses with an atraumatic needle
- Developed by Grippol® Vaccine Technology
1. WHO WER 2012;87(21):201–216;
2. Pieter T. de Boyer et al. Cost-effectiveness of Quadrivalent versus
Trivalent influenza vaccine in tde United State.//Value in Healtd 2016; 19: 964-975;
3. А.В. Рудакова, С.М. Харит, А.Н. Усков, Ю.В. Лобзин, Предотвращенный ущерб при вакцинации против гриппа 3-х и 4-х валентными вакцинами, Журнал
Инфектология, том 9, №2, 2017;
4.HUMAN VACCINES & IMMUNOTHERAPEUTICS 2017, VOL 13, NO. 7, 1640–1652
https://dol.org/10.1080/21645515.2017.1313375;